| VBI Vaccines is a biopharmaceutical company. Co. is developing the prevention and treatment of hepatitis B, with trivalent hepatitis B vaccine, Sci-B-Vac, which is approved for use and available in Israel; and with VBI-2601 (BRII-179), an immunotherapeutic candidate in development for a functional cure for chronic hepatitis B. Co.'s enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. Co.'s primary eVLP program candidates include a glioblastoma vaccine immunotherapeutic candidate, VBI-1901, and a prophylactic cytomegalovirus vaccine candidate, VBI-1501. We show 20 historical shares outstanding datapoints in our coverage of VBIV's shares outstanding history.|
Understanding the changing numbers of VBIV shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VBIV versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VBIV by allowing them to research VBIV shares outstanding history
as well as any other stock in our coverage universe.